Market Overview

Piper Jaffray Maintains Neutral on Isis Pharmaceuticals, Inc., Lowers PT to $9.00

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for ISIS

DateFirmActionFromTo
Dec 2015Wells FargoInitiates Coverage onOutperform
Nov 2015Goldman SachsInitiates Coverage onNeutral
Nov 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (ISIS)

Get Benzinga's Newsletters